Dozens of “targeted” drugs are emerging, backed by unprecedented investment by pharmaceutical companies, which could profit from drugs that prolong life even by weeks.
By AMY HARMON, New York Times
Sun, 02/21/2010 - 9:39pm
Dozens of “targeted” drugs are emerging, backed by unprecedented investment by pharmaceutical companies, which could profit from drugs that prolong life even by weeks.